Difference between revisions of "Pancreatic cancer - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
m (Text replacement - "style="background-color:#1a9851" |Phase III" to "style="background-color:#1a9851" |Phase 3") |
||
Line 26: | Line 26: | ||
|[https://www.tandfonline.com/doi/abs/10.1179/joc.2004.16.6.589 Cantore et al. 2004] | |[https://www.tandfonline.com/doi/abs/10.1179/joc.2004.16.6.589 Cantore et al. 2004] | ||
|1997-2001 | |1997-2001 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[Pancreatic_cancer#Gemcitabine_monotherapy_2|Gemcitabine]] | |[[Pancreatic_cancer#Gemcitabine_monotherapy_2|Gemcitabine]] | ||
| style="background-color:#91cf60" |Seems to have superior OS | | style="background-color:#91cf60" |Seems to have superior OS | ||
Line 59: | Line 59: | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(05)70175-3/abstract Reni et al. 2005] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(05)70175-3/abstract Reni et al. 2005] | ||
|2000-2003 | |2000-2003 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[Pancreatic_cancer#Gemcitabine_monotherapy_3|Gemcitabine]] | |[[Pancreatic_cancer#Gemcitabine_monotherapy_3|Gemcitabine]] | ||
| style="background-color:#91cf60" |Seems to have superior PFS | | style="background-color:#91cf60" |Seems to have superior PFS | ||
Line 94: | Line 94: | ||
|[https://doi.org/10.1002/1097-0142(19910901)68:5%3C965::aid-cncr2820680509%3E3.0.co;2-2 Kelsen et al. 1991] | |[https://doi.org/10.1002/1097-0142(19910901)68:5%3C965::aid-cncr2820680509%3E3.0.co;2-2 Kelsen et al. 1991] | ||
|1987-1989 | |1987-1989 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|CAC | |CAC | ||
| style="background-color:#1a9850" |Superior OS | | style="background-color:#1a9850" |Superior OS |
Revision as of 02:18, 16 December 2021
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main pancreatic cancer page for current regimens.
3 regimens on this page
3 variants on this page
|
Induction therapy for locally advanced disease, unresectable
FLEC
back to top |
FLEC: Fluorouracil, Leucovorin (Folinic acid), Epirubicin, Carboplatin
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cantore et al. 2004 | 1997-2001 | Phase 3 (E-esc) | Gemcitabine | Seems to have superior OS |
Chemotherapy
References
- Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. link to original article PubMed
Metastatic disease, first-line
PEFG
back to top |
PEFG: Platinol (Cisplatin), Epirubicin, Fluorouracil, Gemcitabine
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Reni et al. 2005 | 2000-2003 | Phase 3 (E-esc) | Gemcitabine | Seems to have superior PFS |
Chemotherapy
- Cisplatin (Platinol) 40 mg/m2 IV once on day 1
- Epirubicin (Ellence) 40 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 5600 mg/m2)
- Gemcitabine (Gemzar) 600 mg/m2 IV over 60 minutes once per day on days 1 & 8
28-day cycles
References
- Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. link to original article contains protocol PubMed
Metastatic disease, all lines of therapy
SMF
back to top |
SMF: Streptozotocin, Mitomycin, 5-Fluorouracil
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kelsen et al. 1991 | 1987-1989 | Phase 3 (C) | CAC | Superior OS |
Chemotherapy
References
- Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. link to original article PubMed